



08-02-04, FWD, 1615

*JF*  
Docket No. 58070 CPA (47126)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: G. Cevc Confirmation No.: 2670

U.S.S.N.: 09/284,683 Group No.: 1615

FILED: June 24, 1999 Examiner: G.S. Kishore

FOR: PREPARATION FOR THE TRANSPORT OF AN ACTIVE  
SUBSTANCE ACROSS BARRIERS

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 02209-9169

08/03/2004 NROCHA1 00000005 09284683

01 FC:1806

100.00 OP

\*\*\*\*\*

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail, Label No. EV 437 825 090 US addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: July 30, 2004

By:

*Judy Daley*  
Judy Daley

\*\*\*\*\*  
Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

**REMARKS**

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

\_\_\_\_ (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or

\_\_\_\_ (2) within three months of the mailing date of the Search Report issued by the PCT Patent Office; or

X      (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or

      \_\_\_\_ (4) after the mailing date of a **Final Rejection or Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO-1449 be made of record in this application. Copies of these documents (CHECK ONE):

X      are enclosed herewith; or

      \_\_\_\_ have been cited in the parent application, and are thus not being resubmitted herein.

#### FEE AUTHORIZATION

Enclosed herewith is a check in the amount of \$180.00 for submission of these cited references. Should any additional fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 04-1105. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,




---

Peter F. Corless (Reg. No. 33,860)  
Edwards & Angell, LLP  
P.O. Box 55874  
Boston, MA 02205  
(617) 439-4444

Date: July 30, 2004

Customer No.: 21874


**INFORMATION DISCLOSURE CITATION**  
*(Use several sheets if necessary)*

 ATTY DOCKET NO.  
**58070 CPA (47126)**

 SERIAL NO.  
**09/284,683**
**Applicant(s): G. CEVC**
**FILING**
**June 24, 1999**
**GROUP**
**1615**
**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	TRADE NAME IF APPLICABLE	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA		5,607,692	04/04/1997	Ribier et al.	424	450	
AB		5,958,379	28/09/1999	Regenold et al.	424	47	
AC		4,944,948	31/07/1990	Uster et al.	424	450	
AD		5,322,685	21/06/1994	Nakagawa et al.	424	78.03	
AE		5,238,613	24/08/1993	Anderson	264	22	
AF		Re. 33,273	24/07/1990	Speaker	210	639	
AG		4,921,706	01/05/1990	Roberts et al.	424	450	
AH		4,619,794	28/10/1986	Hauser	264	4.1	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
BA		07-324029	12.12.1995	JP				
BB		0 298 280	14.06.1988	EP				
BC		0 674 913	04.10.1995	EP				
BD		0 707 847	24.04.1996	EP				
BE		0 704 206	03.04.1996	EP				

**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	CA	G. Cevc et al., Transdermal drug carriers: basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides, <i>J. Contr. Rel.</i> , 36, pp. 3-16, 1995
	CB	G. Cevc, Transfersomes, Liposomes and Other Lipid Suspensions on the Skin: Permeation Enhancement, Vesicle Penetration, and Transdermal Drug Delivery, <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 13(3&4), pp. 257-388, 1996

**EXAMINER**
**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(use several sheets if necessary)

JUL 30 2004

Docket Number (Optional)

58070 CPA (47126)

Application Number

09/284,683

Applicant(s)

G. CEVC

Filing Date

June 24, 1999

Group Art Unit

1615

PCT  
EXAMINER  
TRADEMARK COORDINATOR

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CC	A. Klibanov, et al., Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target, <i>BBA</i> , 1062, pp. 141-148, 1991
	CD	L. Löbbecke, et al., "Effects of Short-Chain Alcohols On the Phase Behavior And Interdigitation Of Phosphatidylcholine Bilayer Membranes," <i>Biochimica et Biophysica Acta</i> , 1237, pp. 59-69, 1995
	CE	R. Singh, et al., "Liposomally Encapsulated Diclofenac For Sonophoresis Induced Systemic Delivery," <i>J. Microencapsulation</i> , Vol. 12, No. 2, pp. 149-154, 1995
	CF	T. Henmi, et al., "Application of an Oily Gel Formed by Hydrogenated Soybean Phospholipids as a Percutaneous Absorption-Type Ointment Base," <i>Chem. Pharm. Bull.</i> , 42(3), pp. 651-655, 1994
	CG	M. Foldvari, et al., "Dermal Drug Delivery by Liposome Encapsulation: Clinical and Electron Microscopic Studies," <i>J. Microencapsulation</i> , Vol. 7, No. 4, pp. 479-489, 1990
	CH	M. Foldari, "In Vitro cutaneous and Percutaneous Delivery and in Vivo Efficacy of Tetracaine from Liposomal and Conventional Vehicles," <i>Pharmaceutical Research</i> , Vol. 11, No. 11, 1994
	CI	M. Foldari, "Effect of Vehicle on Topical Liposomal Drug Delivery: Petrolatum Bases," <i>J. Microencapsulation</i> , Vol. 13, No. 5, pp. 589-600, 1996
	CJ	M.E. Planas, et al., "Noninvasive Percutaneous Induction of Topical Analgesia by a New Type of Drug Carrier, and Prolongation of Local Pain Insensitivity by Anesthetic Liposomes," <i>Anesth. Analg.</i> , 75, pp. 615-621, 1992
	CK	H. Peters, et al., "Pharmacodynamics of a Liposomal Preparation for Local Anaesthesia," <i>Arzneim.-Forsch./Drug Res.</i> , 45(II), Nr. 12, 1995
	CL	Blume, et al., "Drug-Carrier and Stability Properties of the Long-Lived Lipid Vesicles, Cryptosomes, in Vitro and in Vivo," <i>Journal of Liposome Research</i> , 2(3), pp. 355-368, 1992

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.